Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 837-841

  Mandal, Rakesh ^a   Bolt, Daniel M ^b   Shah, Binay K ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c St Joseph Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CAUCASIAN; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DATA BASE; ETHNICITY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE; UNITED STATES; AFRICAN AMERICAN; AGE; AGED; CANCER REGISTRY; ETHNIC DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; ETHNIC GROUPS; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SEER PROGRAM; SEX CHARACTERISTICS; SURVIVAL RATE; UNITED STATES;

EID: 84875946425     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.707784     Document Type: Article

References (15)

1. Hughes TP, Kaeda J, B ranford S, R udzki Z, HochhauSa, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32.
2. Hochhau Sa, O'Brien SG, G uilhot F, D ruker BJ, B ranford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the fi rst-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-61.
3. Baccarani M, D reyling M; ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v165-7.
4. George S, H orvath L, M olokie R, B erry J, R ondelli D, Hoffman R, editors. Response to Therapy with imatinib mesylate in patients with CML is poor in non-caucasian patients. ASH Annual Meeting Abstr; 2004; 104: 2937.
5. Gloeckler Ries LA, Reichman M E, L ewis D R, H ankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, anDend Results (SEER) program. Oncologist 2003; 8: 541-52.
6. Surveillance, Epidemiology, anDend Results (SEER) Program (www.seer.cancer.gov) SEER * Stat Database: Incidence-SEER 17 Regs Research Data-Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying)-Linked To County Attributes-Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
7. Brown CC. The statistical comparison oFrelative survival rates. Biometrics 1983; 39: 941-8.
8. Kantarjian H M, T alpaz M, O'Brien S, J ones D, G iles F, Garcia-Manero G, et al. Survival benefi t with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835-40.
9. de Lavallade H, M ilojkovic D, K horashad J, Reid A, Olavarria E, Kaeda J, et al. Outcome, prognostic factorSand long-term follow-up in 207 chronic phase CML patients receiving front-line imatinib 400 mg at a single institution. ASH Annual Meeting Abstr 2007; 110: 1045.
10. Lucas CM, W ang L, A ustin GM, K night K, W atmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates loweRefficacy than in clinical trials. Leukemia 2008; 22: 1963-6.
11. Wiggins CL, H arlan LC, N elson HE, S tevens JL, W illman CL, Libby EN, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 2010; 123: 764.e1-9.
12. Brenner H, GondoSa, P ulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Haematologica 2008; 93: 1544-9.
13. Thygesen LC, N ielsen OJ, J ohansen C. T rends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control 2009; 20: 1671-80.
14. Cella DF, Orav EJ, Kornblith A B, Holland JC, Silberfarb PM, Lee KW, et al. Socioeconomic statuSand cancer survival. J Clin Oncol 1991; 9: 1500-9.
15. Singh GK, M iller BA, H ankey BF, E dwards BK. A rea socioeconomic variations in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975-1999. NCI Cancer Surveillance Monograph Series. Number 4. Bethesda: National Cancer Institute; 2003.